Submited on: 02 Dec 2011 06:28:00 PM GMT
Published on: 03 Dec 2011 08:06:07 PM GMT
Case Report Limits from the Author (Avoid Abuse)
Posted by Dr. Bill Misner on 04 Dec 2011 05:45:38 AM GMT


In order to review this case report, please read it carefully, especially the last sentence in each of the Abstract, Discussion, and Conclusion sections. Please also consider 34-esteemed scholarly reviewers posted reviews on 4-previous revised versions of this final case report. Each revised versions averaged between 5-8. Revision II 5.7, Revision III 7.5, Revision IV 6.8. Therefore, if now on the final Revision V, if a reviewer posts less than "5" and states the reason is a case report is not conclusive, then we may conclude the reviewer has neither read the article nor knows what a case report is and how science method includes case reports in the literature.

A Case Report may examine cause-and-effect associations with a single-subject. For 194-days a single subject consumed either 400-mg/d Ubiquinol or  400-mg/d Ubiquinone or no supplement dose. At the beginning of each timed trial on the same 15K-trail course the subjects resting heart rate range was between 51-56 or no timed run was recorded due to the subject not being properly rested prior to timed run. At the end of each of 21-timed trail runs on the same 15-K course, the subject's finishing heart rate was 156-164 which according to the Karvonnen Formula is 105-110% Maximum Heart Rate, indicating the subject had given over a Maximum Heart Rate effort. Oral dose Ubiquinol and Ubiquinone have been scientifically reported to raise steady state serum Coenzyme Q10 levels. One manufacturer states Ubiquinol raises serum level higher than Ubiquinone. Another manufacturer states that Ubiquinol and Ubiquinone equally raise steady state circulatory levels. Until now no report has measured the effect of the po-dose past circulation in the mitochondria where Ubiquinol and Ubiquinone are rapidly depleted during endurance exercise, and more so in elderly subjects. This is a case report that is bluntly informative but inconclusive (see below) of a single subject who recorded best performance when consuming Ubiquinone, not Ubiquinol, not taking any supplement.

The last sentence in the Abstract, Discussion, and Conclusion sections specifically qualify limits for this unique finding.

Abstract {Last Sentence}
The results from a single male subject are definitively inconclusive, but call for more research by collecting dose-aided and dose-fasted timed performances from a larger contingent of male and female runners of all ages.

Discussion: {Last Sentence}
It must be emphasized that what occurred with this single male runner is a single case report, not a conclusive finding applicable to all populations.

Conclusion: {Last Sentence}
To determine whether or not performance is associated with exogenous Ubiquinone or Ubiquinol, more research is required by examining exogenous Ubiquinone and Ubiquinol-dose effects in larger contingents of male and female runners of all age ranges.

Warm regards,

Dr. Bill Misner, Ph.D. {Emeritus}

AAMA Board Certified Alternative Medicine Practitioner Certification #32872409

Alternative Medicine Faculty & Advisory Board (2011)
WebMedCentral @

  • competing interests: None.
  • Invited by the author to make a review on this article? :
  • Experience and credentials in the specific area of science:

    AAMA Board Certified Alternative Medicine Practitioner



  • Publications in the same or a related area of science: No
  • References: None
Report abuse